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engue vaccine late stage development update
. Lang
Sanoﬁ Pasteur, Lyons, France
Research into developing a vaccine against dengue began more
han 60 years ago. Sanoﬁ Pasteur joined this international research
rogram in 1994 and in 2010 phase III studies of a tetravalent
engue vaccine started throughout Asia Paciﬁc and Latin America.
Sanoﬁ Pasteur’s candidate vaccine—the CYD TDV—is a recom-
inant, live, attenuated, vaccine administered subcutaneously in a
-dose, 0–6–12 month regimen. 28 000 children and adults have
eceived 31 dose of vaccine as ofMarch 2012. A pooled safety analy-
is on1728CYDTDVvaccinees, 549active controls, and490placebo
ontrolswas done from the eleven completed Phase I/II trials. Over-
ll for dengue vaccines, the proportions of subjects reporting at
east one reaction decreased after the 3 successive doses. Results
ere not affected by either ﬂavivirus immune status at inclusion or
ge at vaccination. The observed safety proﬁle of the CYD TDV can-
idate is comparable to that of licensed control vaccines. Overall
he safety proﬁle of TDV is considered as satisfactory. In a series of
hase II studies performed in endemic and non endemic countries,
7%–100% of vaccinees are seropositive (PRNT50 titre ≥10) to all
our serotypes after three doses of TDV. Moreover, the results of
-years of immunogenicity follow-up of 80 Vietnamese adults and
hildren showed a good persistence of neutralizing antibodieswith
5% of the subjects still seropositive against the 4 serotypes three
ears post dose-3, although possibly boosted by natural exposure.
The next major milestone for this much-needed vaccine against
engue disease is the availability before the end of 2012 of the ﬁrst
fﬁcacy results from a study of 4000 children aged 4–11y in Ratch-
buri, Thailand. Assuming positive results of this efﬁcacy trial, the
icensure of this vaccine in highly endemic countries is expected to
ccur within the next 2 -4 years.
ttp://dx.doi.org/10.1016/j.ijid.2012.05.016
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otential impact of dengue vaccination: a modeling approach
. Massad
Universidade de Sao Paulo, Sao Paulo, Brazil
Dengue is a major public health concern in Brazil. Dengue
accines should help, when available, to signiﬁcantly reduce the
urden of dengue but raise a number of question around their best
se. In this context, mathematical models can provide insights onnfectious Diseases 16S (2012) e2–e157 e5
questions such as optimal age for vaccination or respective beneﬁts
of routine and catch-up vaccination at different coverage rates.
We ﬁrst present analytical results related to the optimal age for
vaccination and expected beneﬁts from catch-up campaigns using
the most recent seroprevalence data available for Brazil. We then
present the results obtained with an age-structured, host-vector
compartmental model that captures seasonality and interactions
between the four dengue serotypes. This model was adapted to
the Brazilian situation through the use of surveillance data for
age and severity-speciﬁc incidence as well as available informa-
tion on vector density and dengue seroprevalence according to age.
Both analyses lead to the conclusion that starting routine vaccina-
tion at an early age (2 years of age) provides the largest reduction
of dengue incidence per vaccine dose administered whatever the
force of infection, vaccine coverage or efﬁcacy considered. Rou-
tine vaccination alone is however expected to get a limited impact
on dengue incidence the ﬁrst year of its implementation. Com-
plementing routine vaccination by catch-up campaigns enables to
obtain very rapidly a high level of disease control if offered to a
sufﬁcient number of cohorts (e.g. children from 3 to 14 years of
age). The results of an ongoing efﬁcacy and large scale safety study
should help to reﬁne the results on the beneﬁts expected from a
dengue vaccination program.
http://dx.doi.org/10.1016/j.ijid.2012.05.017
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Roadmap for successful dengue vaccine introduction
R. Tapia-Conyer
Instituto Carlos Slim de la Salud, Mexico City, Mexico
Worldwide dengue epidemics continue to increase; climate
change, growing urbanization and migration patterns predict our
scenario. These epidemiological and sociological conditions impose
an overwhelming economic burden and use of health services due
to dengue’s high morbidity in all socioeconomically strata. Up to
now, the most commonly used control strategy against dengue has
been vector control, which has proven limited effectiveness.
Thanks to R&D efforts a safe and effective dengue vaccine could
become available in the near future. In this paramount, the coun-
tries develop preparedness plans for the introduction of a dengue
vaccine that ought to include:
- Determination of the real dengue burden of disease, by
strengthening information systems and developing speciﬁc epi-
demiological studies.
- Development of a vaccine introduction strategy: deﬁning speciﬁc
target populations, strengthening vaccine delivery platform, and
training.
- Adjustment of the regulatory requirements, to allow proper and
timely licensing of the new vaccine.
- Implementation of econometric studies to estimate costs
involved in the vaccine introduction and cost-effectiveness anal-
ysis.
- Strengthening dengue prevention and control programs.
- Ensuring budgetary resources.
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Preparation of health promotion and social dissemination strat-
egy to ensure an adequate uptake of the vaccine.
The development of a preparedness plan requires the leader-
hip and active participation of all interested parties: public health
gencies, academic bodies, research groups, regulatory authority
nd operational organizations focusing on ﬁve strategic areas:
Epidemiological information and burden of disease.
Vaccine introduction strategy and operative elements.
Legal and regulatory issues.Economic and ﬁnancial issues.
Social communication and health promotion.
Science, technology and human creativity, have come together
o provide a public health innovation with great impact, to prevent
worldwide high burden disease; it is imperative for governments
nd society to ensure that this new tool, be incorporated in the
ational immunization programs and therefore reaching dengue
ontrol.
ttp://dx.doi.org/10.1016/j.ijid.2012.05.018
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nfectious diseases among refugees in Beirut
. Beldjebel
Charles Foucauld Health Ctr, Beirut, Lebanon
Background: With the Iraqi war launched on 2003, more than 2
illion Iraqi became refugees in neighboring countries, as Lebanon.
The characteristic of these refugees is that they are urban
efugees from a middle income country, with satisfactory basic
tate of health.
Methods: Our study was conducted among Iraqi refugees in a
eirut suburb, and compared with studies.
Results
Infectious Diseases: The epidemiology of some infectious dis-
ases in Iraqi refuges differs from other refugees group, the
revalence of abnormal chest radiograph (0.7%); culture conﬁrmed
B (0%) hepatitis B (0.7%) and intestinal parasites was much lower
han those in other recent refugee population resettled in the
nited States.
Chronic Diseases:
Whereas the prevalence of infectious diseases is not problem-
tic, the prevalence of chronic diseases represents the main public
ealth problem for this population. Our study conducted among
he Iraqi population over the age of 40 years old, in Beirut suburb,
ound out a prevalence of 51.25% for obesity, 44% dyslipidemia,
2.5% hypertension, 18% diabetes I, 7% diabetes II, and 17.5% for the
ombination of hypertension and diabetes, with a higher preva-
ence among the male population: 65% vs. 35% for hypertension,
0% vs. 40% diabetes and71 vs.29 for hypertension and diabetes.
The main reasons are the sedentary life style, obesity, the stress,
igh level of salt intake, smoking, genetics and family history.
Mental Health Diseases: High rates of mental health concerns
ave been documented in various refugee populations, with a high
ate of post –traumatic stress disorder.nfectious Diseases 16S (2012) e2–e157
From observations based on distress indicators, more than 50%
of the families in Lebanon presented at least 8 indicators. The cross
analyses of these results shows that Iraqi refugees are undergoing
a period of serious emotional and psychosocial threats that create
widespread distress in living environment.
Conclusion: Diseases prevalence vary greatly between refugees
fromdifferent countries, some infectious conditions that have been
the traditional focus of refugee health assessment such as tuber-
culosis, cholera, intestinal infections are not prevalent in Iraqi
refugees, but non- infectious, chronic conditions, such as obesity,
hypertension, diabetes, dyslipidemia, are prevalent and important
concerns in this population, mental health issues should also be
considered and screened.
http://dx.doi.org/10.1016/j.ijid.2012.05.019
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Infectious diseases in orphanages in South-east Asia
J. Benca
The Clinic of St. Maximillian Kolbe, House of Family, Phnom Penh,
Cambodia
There are not enough relevant data about infectious diseases
from children living in orphanages. Mostly, information come from
children who were adopted to western developed countries, and
they yearly count for 75 000. Very often, orphans are suffering from
malnutrition and excessive number of infectious diseases such as
respiratory tract infections, intestinal parasites, HIV, opportunistic
infections and tuberculosis.
Cambodia belongs to one of the most HIV-affected countries in
South-East Asia region. Prevalence of HIV has tendency to decrease
as in 2007 it was 0,8%.
St. Elizabeth University has been running tropical program for
HIV positive children in Phnom Penh and Sihanouquille in Cam-
bodia since 2003. One hundred and two children (n=102) treated
with HAART were included in the study. During 6 years we have
observed different spectrum of infectious diseases in orphans.
Themost prevalent complicationwas pneumonia in 65% of chil-
dren, followed by pyodermia in 64%, tuberculosis in 48%, Otitis
media chronica in 38%, oropharyngeal candidiasis in 34%, paroti-
tis recurrens in 24%, vasting syndrome in 23%, herpes zoster in 23%,
persistent diarrhea in 10%, hepatitis B in 6%. Mortality was 2,99%
in this period. Due to several episodes of opportunistic infections,
HIV infected children received multiple courses of antimicrobial
therapy, most often for treatment of (i) respiratory tract infections
(cephalosporins, aminopenicillins,macrolides), (ii) candidiasis (ﬂu-
conazole) and (iii) Herpes infections (acyclovir, valacyclovir). Nose
and throat swabs were taken every three months. At the start of
HAART, all isolatesofEnterobacter spp. andKlebsiela spp.were resis-
tant to cefotaxim. Interestingly, after three years of treatment with
HAART, neither Enterobacter spp. nor Klebsiela spp. isolates were
resistant to cefotaxim at all.
In conclusion, we found out, that, reconstitution of immune
status and increase of CD4 T-cells level as a result of HAART was
associated with decreased colonization with cefotaxim-resistant
Enterobacter sp. and Klebsiela spp. isolates in HIV-infected children.
http://dx.doi.org/10.1016/j.ijid.2012.05.020
